CASE REPORT
A 43 year-old Caucasian man with a history of HIV with a CD4 count of 530 cells/mm3, not currently on HAART, presented with left-sided proptosis, headaches, and eye pain. Three months prior to this admission, he was seen for a jaw abscess for which his doctors prescribed clindamycin. CT scanning ( Figure 1 ) and MR imaging ( Figure 2 ) on this admission for proptosis revealed a left retro-orbital mass measuring 4.5 cm by 3.0 cm by 4.0 cm with bony erosion of the sphenoid wing and mass effect on the left globe and compression of the anterior left temporal lobe as well as a soft tissue mass near the right fossa of Rosenmüller in the right nasopharynx.
PET/CT imaging revealed hypermetabolic activity of the left retro-orbital mass ( Figure 3A ) with a maximal SUV of 30.0 and right nasopharyngeal mass in the fossa of Rosenmüller ( Figure 3B ) with maximal SUV of 31.7 as well as diffuse lymphadenopathy in the neck, abdomen, and pelvis with maximal SUV of 4.5.
Biopsy of the nasopharyngeal mass demonstrated proliferation of medium to large sized lymphoid type cells with prominent nucleoli and numerous mitotic figures on frozen section; these neoplastic cells are positive for CD10 and CD138 and weakly positive for CD79a, consistent with the diagnosis of plasmablastic lymphoma.
The patient was placed on a regimen of EPOCH chemotherapeutic agents (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone) and pegfilgrastim. Follow-up MR imaging ( Figure 4 ) demonstrated a precipitous reduction in the size of the lesion at two months, and PET/CT at five months does not show any recurrence or metastatic disease. At ten months, however, PET/CT revealed areas of hypermetabolic activity suggestive of recurrence of PBL most prominently in the retromandibular and posterior cervical lymph nodes ( Figure 5 ) with a new lesion in the Rosenmüller's fossa of the left nasopharynx. No recurrence of the orbital lesion was noted, however. The patient continues to be followed up with PET/CT routinely and otolaryngology is expected to biopsy the new hypermetabolic lesions and assess whether these regions of high SUV indicate recurrence or a new primary cancer such as nasopharyngeal carcinoma.
This case is an unusual example of plasmablastic lymphoma, originating in the right nasopharynx of an HIVpositive man. The lesion spread to the left retro-orbital region. Possible explanations of his initial clinical presentation include a host possible conditions ranging from orbital cellulitis, a retro-ocular hemangioma or AVM, a spheno-orbital meningioma, cavernous sinus thrombosis, Grave's disease to, most rarely, lymphoma. The lack of bony erosion on CT imaging in this case argues against the presence of hemangioma and the retro-orbital position and discrete mass supports diagnoses other than orbital cellulitis, Grave's disease or cavernous sinus thrombosis.
While there are several potential causes for the initial CT and MR imaging appearance of an enhancing mass located in the retro-orbital region (highlighted in the differential diagnosis table) that could explain this patient's proptosis and constellation of symptoms, functional imaging was able to provide clues to support the eventual diagnosis. Initial imaging with PET/CT demonstrating hypermetabolic activity largely restricted the differential diagnosis in this patient to malignancy and also suggested these lesions to be primary within the head rather than metastatic disease from elsewhere. Etiologies possible of producing this set of imaging findings therefore include glioblastoma multiforme, primary CNS lymphomas, and spheno-orbital meningioma. The clinical team could narrow the diagnosis in this case because of the presence of a lesion within the nasopharynx, biopsy could be performed. Pathological examination of this lesion made the definitive diagnosis of PBL. The presence of lymphadenopathy with hypermetabolic uptake of FDG in addition to the nasopharyngeal and retro-orbital masses supported the early initiation of chemotherapy. Unlike many reported cases of PBL, this patient's lesions responded well to EPOCH chemotherapy with complete remission on PET/CT at five months. Unfortunately, recurrence of hypermetabolic lesions was seen at ten months on PET/CT.
Nevertheless, this duration of remission is greater than most reported cases, yet no clearly established response rates exist for EPOCH chemotherapy in PBL cases. This case demonstrates the utility of PET/CT imaging in the staging of this rare cancer as well as its usefulness in assessing for recurrence.
Plasmablastic lymphoma (PBL), an aggressive nonHodgkin's lymphoma, is a recently identified form of diffuse large B-cell lymphoma (DLBCL) first described in 1997; this clinical entity is extremely rare with only about 60 cases reported [1] . On pathology, it is characterized by immunoblastic morphology of large cells with abundant cytoplasm and eccentric nuclei with positive staining for CD138 and VS38c [1, 2] . These neoplastic cells do not express CD20 and CD45. PBL, like other Non-Hodgkins Lymphomas (NHL) is seen with greater frequency in immunosuppressed HIV patients and may even constitute the initial presentation of HIV, but approximately ten percent of cases of PBL occur in HIV-negative individuals [3, 4] . EpsteinBarr Virus (EBV) and Human Herpes Virus 8 (HHV-8) may be responsible for initiation of neoplastic activity in PBL as identified in 76% and 37% of cases, respectively [1] . PBL classically manifests in the form of oral lesions and even led to its naming by the World Health Organization as plasmablastic lymphoma of the oral cavity, but more evidence suggests that extra-oral presentations of PBL occur with substantial frequency including cases of orbital, cutaneous, gastrointestinal and other manifestations [1, [5] [6] [7] . One review of the literature demonstrates oral lesions to comprise threequarters of PBL cases [4] . A few cases of orbital PBL similar to that reported here exist in the literature [8, 9] .
Prognosis is generally poor, yet poorly quantified in the literature; a meta-analysis reports a death rate of 60% at 10 months follow-up and another study reports an average survival time of six months [1, 8] . There exists little evidence to support a particular treatment approach to manage PBL. PBL may respond to HAART therapy in HIV-positive as suggested by one case report and a meta-analysis demonstrating greater survival in HIV patients receiving HAART [1, 10] . CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) multi-agent chemotherapy is also purported to promote remission of PBL, but success rates vary in the literature and most cases recur [4] . One group reports success with HAART combined with CHOP in treating PBL [11] . As utilized by the clinical treatment team in this case, EPOCH chemotherapy is a standard chemotherapeutic regimen for HIV-associated lymphomas and has demonstrated varied efficacy in a small number of cases [12, 13] . Spontaneous remission has even been reported in one particular case [14] .
We report here the imaging findings of a rare case of orbital PBL. MR Imaging in this case demonstrates excellent response to EPOCH chemotherapy with reduction of the retroocular lesion. Imaging also clarified the extent of invasion of this lesion and provided reassurance of non-parenchymal involvement.
PET/CT is of the utmost importance in following up the progression of this disease, especially in light of PBL's highly aggressive nature. Close monitoring of this patient has revealed potential recurrence of PBL and will continue to play an important role in assessing this patient's needs for chemotherapy and radiotherapy. In addition, PET/CT in this case has provided probable sites of malignancy to be biopsied to better stage this patient's cancer.
Plasmablastic lymphoma may manifest in extra-oral locations such as the orbit, most commonly in patients with a history of AIDS. On imaging, PBL appears as a soft tissue mass differentiated from several other etiologies by avid FDG uptake on PET/CT scanning and is definitively diagnosed by characteristic histological markers on pathological examination. . 43-year-old male with history of HIV with diagnosed plasmablastic lymphoma underwent PET/CT after five rounds of EPOCH chemotherapy ten months after initial diagnosis. Seen on this study is marked hypermetabolic activity within the submandibular glands bilaterally with a maximal SUV of 7.9. (Protocol: 14.8 millicuries of F-18 labeled FDG for the uptake interval, both emission and transmission scans of the whole body from lower head to mid thigh were obtained. Emission and attenuation corrected 3-D cine, transverse, coronal and sagittal images were reviewed on a workstation. The standardized uptake values were calculated using the patient's ideal body weight. A low dose spiral CT scan from the lower head to mid thigh is fused to the PET data for anatomical localization as needed.)
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